109 related articles for article (PubMed ID: 6236189)
1. Marked radiosensitization of cells in culture to X ray by 5-chlorodeoxycytidine coadministered with tetrahydrouridine, and inhibitors of pyrimidine biosynthesis.
Perez LM; Mekras JA; Briggle TV; Greer S
Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1453-8. PubMed ID: 6236189
[TBL] [Abstract][Full Text] [Related]
2. Sensitization to X ray by 5-chloro-2'-deoxycytidine co-administered with tetrahydrouridine in several mammalian cell lines and studies of 2'-chloro derivatives.
Perez LM; Greer S
Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1523-7. PubMed ID: 3759575
[TBL] [Abstract][Full Text] [Related]
3. Radiation, pool size and incorporation studies in mice with 5-chloro-2'-deoxycytidine.
Santos O; Perez LM; Briggle TV; Boothman DA; Greer SB
Int J Radiat Oncol Biol Phys; 1990 Aug; 19(2):357-65. PubMed ID: 2394614
[TBL] [Abstract][Full Text] [Related]
4. Five-chlorodeoxycytidine, a tumor-selective enzyme-driven radiosensitizer, effectively controls five advanced human tumors in nude mice.
Greer S; Alvarez M; Mas M; Wozniak C; Arnold D; Knapinska A; Norris C; Burk R; Aller A; Dauphinée M
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(3):791-806. PubMed ID: 11697326
[TBL] [Abstract][Full Text] [Related]
5. Five-chlorodeoxycytidine and biomodulators of its metabolism result in fifty to eighty percent cures of advanced EMT-6 tumors when used with fractionated radiation.
Greer S; Schwade J; Marion HS
Int J Radiat Oncol Biol Phys; 1995 Jul; 32(4):1059-69. PubMed ID: 7607927
[TBL] [Abstract][Full Text] [Related]
6. Metabolic channeling of 5-fluoro-2'-deoxycytidine utilizing inhibitors of its deamination in cell culture.
Boothman DA; Briggle TV; Greer S
Mol Pharmacol; 1985 May; 27(5):584-94. PubMed ID: 2581125
[TBL] [Abstract][Full Text] [Related]
7. Selective radiosensitization and cytotoxicity of human melanoma cells using halogenated deoxycytidines and tetrahydrouridine.
Lawrence TS; Davis MA
Int J Radiat Oncol Biol Phys; 1989 May; 16(5):1243-6. PubMed ID: 2715074
[TBL] [Abstract][Full Text] [Related]
8. 5-chlorodeoxycytidine, a radiosensitizer effective against RIF-1 and Lewis lung carcinoma, is also effective against a DMBA-induced mammary adenocarcinoma and the EMT-6 tumor in BALB/c mice.
Greer S; Santos O; Gottlieb C; Schwade J; Marion HS
Int J Radiat Oncol Biol Phys; 1992; 22(3):505-10. PubMed ID: 1735688
[TBL] [Abstract][Full Text] [Related]
9. Use of 5-fluorodeoxycytidine and tetrahydrouridine to exploit high levels of deoxycytidylate deaminase in tumors to achieve DNA- and target-directed therapies.
Mekras JA; Boothman DA; Perez LM; Greer S
Cancer Res; 1984 Jun; 44(6):2551-60. PubMed ID: 6539164
[TBL] [Abstract][Full Text] [Related]
10. Enzyme-Driven Chemo-and Radiation-Therapy with 12 Pyrimidine Nucleoside Analogs Not Yet in the Clinic.
Greer S; Han T; Dieguez C; McLean N; Saer R; Reis I; Levi J; Marquez VE
Anticancer Agents Med Chem; 2017; 17(2):250-264. PubMed ID: 27745548
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of synergy between N-phosphonacetyl-L-aspartate and dipyridamole in a human ovarian carcinoma cell line.
Chan TC; Howell SB
Cancer Res; 1985 Aug; 45(8):3598-604. PubMed ID: 4016741
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo radiation sensitization by the halogenated pyrimidine 5-chloro-2'-deoxycytidine.
Russell KJ; Rice GC; Brown JM
Cancer Res; 1986 Jun; 46(6):2883-7. PubMed ID: 3698014
[TBL] [Abstract][Full Text] [Related]
13. Aspartate carbamoyltransferase activity, drug concentrations, and pyrimidine nucleotides in tissue from patients treated with N-(phosphonacetyl)-L-aspartate.
Moore EC; Friedman J; Valdivieso M; Plunkett W; Marti JR; Russ J; Loo TL
Biochem Pharmacol; 1982 Oct; 31(20):3317-21. PubMed ID: 7150358
[TBL] [Abstract][Full Text] [Related]
14. Use of 5-trifluoromethyldeoxycytidine and tetrahydrouridine to circumvent catabolism and exploit high levels of cytidine deaminase in tumors to achieve DNA- and target-directed therapies.
Mekras JA; Boothman DA; Greer SB
Cancer Res; 1985 Nov; 45(11 Pt 1):5270-80. PubMed ID: 2932216
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of N-phosphonacetyl-L-aspartic acid in combination with nitrobenzylthioinosine.
Erlichman C; Vidgen D
Biochem Pharmacol; 1984 Oct; 33(20):3177-81. PubMed ID: 6487365
[TBL] [Abstract][Full Text] [Related]
16. Potentiation of halogenated pyrimidine radiosensitizers in human carcinoma cells by beta-lapachone (3,4-dihydro-2,2-dimethyl-2H-naphtho[1,2-b]pyran- 5,6-dione), a novel DNA repair inhibitor.
Boothman DA; Greer S; Pardee AB
Cancer Res; 1987 Oct; 47(20):5361-6. PubMed ID: 3652040
[TBL] [Abstract][Full Text] [Related]
17. PALA enhancement of bromodeoxyuridine incorporation into DNA increases radiation cytotoxicity to human ovarian adenocarcinoma cells.
Yang JL; Fernandes DJ; Wheeler KT; Capizzi RL
Int J Radiat Oncol Biol Phys; 1996 Mar; 34(5):1073-9. PubMed ID: 8600090
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of the weekly intravenous push schedule of 5-fluoro-2'-deoxyuridine +/- N-phosphonacetyl-L-aspartate in mice bearing advanced colon carcinoma 26.
van Laar JA; Durrani FA; Rustum YM
Cancer Res; 1993 Apr; 53(7):1560-4. PubMed ID: 8453623
[TBL] [Abstract][Full Text] [Related]
19. Kinetics of N-(phosphonacetyl)-L-aspartate and pyrazofurin depletion of pyrimidine ribonucleotide and deoxyribonucleotide pools and their relationship to nucleic acid synthesis in intact and permeabilized cells.
Moyer JD; Smith PA; Levy EJ; Handschumacher RE
Cancer Res; 1982 Nov; 42(11):4525-31. PubMed ID: 7127293
[TBL] [Abstract][Full Text] [Related]
20. An overview of the clinical pharmacology of N-phosphonacetyl-L-aspartate (PALA), a new antimetabolite.
Erlichman C
Recent Results Cancer Res; 1980; 74():65-71. PubMed ID: 7444150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
